Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141
Study Details
Study Description
Brief Summary
The purpose of this study was to assess the safety and efficacy of Lumason-enhanced dobutamine stress echo (CE-DSE) in subjects having a suboptimal left ventricular endocardial border delineation (LV EBD) at rest and who were scheduled for coronary angiography.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 3 |
Detailed Description
The study was designed to assess the safety and efficacy of Lumason at improving the visualization of the LV EBD during pharmacologic stress echocardiography examinations and for detection or exclusion of the coronary artery disease (CAD). The study population consisted of adult subjects referred for pharmacological stress echocardiography and with suboptimal image quality during unenhanced ultrasound imaging at rest who had known or suspected CAD. Subjects enrolled in the study represented subjects who could benefit most from contrast-enhanced ultrasound (CEUS) stress echocardiography.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Lumason Lumason (sulfur hexafluoride lipid-type A microspheres) 2 mL IV injection |
Drug: Lumason
Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Sensitivity and Specificity for Detection or Exclusion of Coronary Artery Disease (CAD) [Participants were followed until they had coronary angiography or up to 6 months post dose to collect clinical information on cardiac events if no coronary angiography were performed]
The diagnostic performance of the echocardiographic images was compared to the truth standard to determine sensitivity and specificity. A diagnosis of coronary artery disease (CAD) was determined for both the echo images and truth standard (positive diagnosis for CAD is defined as >/= 50% stenosis of any vessel on coronary angiography or if no coronary angiography is performed the occurence of a cardiac event based on clinical information for up to 6 months post dose; otherwise the diagnosis is negative). Results for sensitivity and specificity are reflected based on difference between contrast enhanced stress echo and unenhanced stress echo. Results for analysis of data based on majority assessment from the three off-site blinded readers are presented. Sensitivity and specificity are the percentages of correctly diagnosed subjects by stress echo over the total positive and negative subjects according to the truth standard respectively.
- Reader-Specific Percentages of Participants Identified as Having a Critical Shift From Suboptimal to Optimal Echocardiographic Images [Participants were followed until they had coronary angiography or up to 6 months post dose to collect clinical information on cardiac events if no coronary angiography was performed]
The percentage of subjects with suboptimal images (defined as >= 2 adjacent segments with inadequate left ventricular endocardial border delineation (LV EBD) in any of the 3 apical views) at unenhanced stress echo converted to adequate (reduction of suboptimal segments in any of the 3 apical views) at contrast-enhanced stress echo
Secondary Outcome Measures
- Change in Total LV EBD [Participants were followed until they had coronary angiography or up to 6 months post dose to collect clinical information on cardiac events if no coronary angiography was performed]
Measured as the change in the total LV EBD score based on the 17 segments, from peak stress unenhanced vs. peak stress contrast-enhanced. Total LV EBD score ranges from 0 to 34 and higher score is better outcome.
- Number of Participants With Adverse Events [up to 72 hours post dose]
To obtain safety data in subjects administered Lumason during echocardiography
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Provided written Informed Consent and was willing to comply with protocol requirements;
-
Was at least 18 years of age;
-
Had suspected or known CAD and was scheduled to undergo coronary angiography within 6 months after the LUMASON DSE.
-
Had undergone a previous echocardiography prior to enrollment; resulting in suboptimal unenhanced images at rest, defined as ≥ 2 suboptimal adjacent segments in any apical view.
Exclusion Criteria:
-
Was a pregnant or lactating female. Excluded the possibility of pregnancy by testing on site at the institution (serum or urine βHCG) within 24 hours prior to the start of LUMASON administration(s), by surgical history (e.g., tubal ligation or hysterectomy), post menopausal with a minimum 1 year without menses;
-
Had any known hypersensitivity to 1 or more ingredients of LUMASON (sulfur hexafluoride or to any components of LUMASON);
-
Had any known hypersensitivity to dobutamine;
-
Had an ongoing or recent (within the last 30 days) acute myocardial infarction;
-
Had known right-to-left, bidirectional or transient cardiac shunt (ruled out with agitated saline study performed before administration of LUMASON);
-
Had electrolyte (especially potassium and magnesium) abnormalities;
-
Had unstable pulmonary and/or systemic hemodynamic conditions e.g.:
-
decompensated or inadequately controlled congestive heart failure (NYHA Class IV);
-
hypovolemia;
-
uncontrolled hypertension, i.e. resting systolic blood pressure >200 mmHg or diastolic blood pressure >110 mmHg;
-
unstable angina;
-
acute coronary syndrome;
-
aortic dissection;
-
acute pericarditis,
-
myocarditis, or endocarditis;
-
stenosis of the main left coronary artery;
-
hemodynamically significant outflow obstruction of the left ventricle, including hypertrophic obstructive cardiomyopathy;
-
hemodynamically significant cardiac valvular defect;
-
acute pulmonary embolism;
-
Had uncontrolled cardiac arrhythmias;
-
Had significant disturbance in conduction;
-
Had hypertrophic subaortic stenosis;
-
Had an acute illness (e.g., infections, hyperthyroidism, or severe anemia);
-
Was previously entered into this study or received an investigational compound within 30 days before admission into this study;
-
Had been treated with any other contrast agent either intravascularly or orally within 48 hours of the first LUMASON administration;
-
Had any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or postdose follow-up examinations;
In addition, due to the use of Atropine in subjects who had not reached targeted heart rate with peak dobutamine infusion, subjects with the following were excluded:
-
Glaucoma;
-
Pyloric stenosis;
-
Prostatic hypertrophy.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Sarver Heart Center, University of Arizona | Tucson | Arizona | United States | 85724 |
2 | University of California San Diego | La Jolla | California | United States | 92037 |
3 | Interventional Cardiology Medical Group, Inc. | West Hills | California | United States | 91037 |
4 | Cardiology Physicians, PA | Newark | Delaware | United States | 19713 |
5 | Community Heart and Vascular Community Hospital East | Indianapolis | Indiana | United States | 46250 |
6 | St. Luke's Mid-America Heart Institute | Kansas City | Missouri | United States | 64111 |
7 | North Kansas City Hospital | North Kansas City | Missouri | United States | 64116 |
8 | Morristown Medical Center | Morristown | New Jersey | United States | 07960 |
9 | The Institute for Clinical Research Holy Name Medical Center | Teaneck | New Jersey | United States | 07666 |
10 | Mount Sinai Medical Center | New York | New York | United States | 10029 |
11 | Mazankowski Alberta Heart Institute, University of Alberta Hospital | Edmonton | Alberta | Canada | T6G2B7 |
12 | Medizinische Klinik m.S. Kardiologie und Angiologie, Charité Universitätsmedizin Berlin | Berlin | Germany | 10117 | |
13 | Klinikum Lünen, St. Marien-Hospital GmbH | Lünen | Germany | 44534 | |
14 | Universitätsmedizin Mainz | Mainz | Germany | 55131 | |
15 | Kardiologie Klinik Dr. Müller GmbH, Peter Osypka Heart Center | Munich | Germany | 81379 | |
16 | Azienda Ospedaliera Universitaria Parma | Parma | Italy | 43126 | |
17 | Azienda Policlinico Umberto I Università degli Studi di Roma La Sapienza | Rome | Italy | 00161 |
Sponsors and Collaborators
- Bracco Diagnostics, Inc
Investigators
- Study Director: Melda Dolan, MD, Bracco Diagnostics, Inc
Study Documents (Full-Text)
More Information
Publications
None provided.- BR1-141
Study Results
Participant Flow
Recruitment Details | |
---|---|
Pre-assignment Detail |
Arm/Group Title | Lumason |
---|---|
Arm/Group Description | Lumason (sulfur hexafluoride lipid-type A microspheres) 2 mL IV injection Lumason: Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography |
Period Title: Overall Study | |
STARTED | 175 |
COMPLETED | 172 |
NOT COMPLETED | 3 |
Baseline Characteristics
Arm/Group Title | Lumason |
---|---|
Arm/Group Description | Lumason (sulfur hexafluoride lipid-type A microspheres) 2 mL IV injection Lumason: Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography |
Overall Participants | 173 |
Age (Count of Participants) | |
<=18 years |
0
0%
|
Between 18 and 65 years |
76
43.9%
|
>=65 years |
97
56.1%
|
Age (years) [Mean (Standard Deviation) ] | |
Mean (Standard Deviation) [years] |
65.0
(10.47)
|
Sex: Female, Male (Count of Participants) | |
Female |
52
30.1%
|
Male |
121
69.9%
|
Race (NIH/OMB) (Count of Participants) | |
American Indian or Alaska Native |
0
0%
|
Asian |
5
2.9%
|
Native Hawaiian or Other Pacific Islander |
0
0%
|
Black or African American |
4
2.3%
|
White |
160
92.5%
|
More than one race |
4
2.3%
|
Unknown or Not Reported |
0
0%
|
BMI (kg/m^2) [Mean (Standard Deviation) ] | |
Mean (Standard Deviation) [kg/m^2] |
30.33
(7.252)
|
Height (cm) [Mean (Standard Deviation) ] | |
Mean (Standard Deviation) [cm] |
169.3
(10.49)
|
Weight (kg) [Mean (Standard Deviation) ] | |
Mean (Standard Deviation) [kg] |
86.99
(21.781)
|
Outcome Measures
Title | Sensitivity and Specificity for Detection or Exclusion of Coronary Artery Disease (CAD) |
---|---|
Description | The diagnostic performance of the echocardiographic images was compared to the truth standard to determine sensitivity and specificity. A diagnosis of coronary artery disease (CAD) was determined for both the echo images and truth standard (positive diagnosis for CAD is defined as >/= 50% stenosis of any vessel on coronary angiography or if no coronary angiography is performed the occurence of a cardiac event based on clinical information for up to 6 months post dose; otherwise the diagnosis is negative). Results for sensitivity and specificity are reflected based on difference between contrast enhanced stress echo and unenhanced stress echo. Results for analysis of data based on majority assessment from the three off-site blinded readers are presented. Sensitivity and specificity are the percentages of correctly diagnosed subjects by stress echo over the total positive and negative subjects according to the truth standard respectively. |
Time Frame | Participants were followed until they had coronary angiography or up to 6 months post dose to collect clinical information on cardiac events if no coronary angiography were performed |
Outcome Measure Data
Analysis Population Description |
---|
Analysis population for coronary artery disease (CAD) included all subjects who received Lumason, had overall diagnostic conclusion of CAD available at peak stress for both UE-DSE and CE-DSE and had a definite truth standard diagnosis (Positive, Negative) for CAD (coronary angiography or 6 months collection of cardiac events follow-up data). |
Arm/Group Title | CE-DSE - UE-DSE |
---|---|
Arm/Group Description | Difference between contrast-enhanced dobutamine stress echo (CE-DSE) and unenhanced dobutamine stress echo (UE-DSE) (CE-DSE - UE-DSE) |
Measure Participants | 170 |
Sensitivity |
8.0
4.6%
|
Specificity |
33.7
19.5%
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | CE-DSE - UE-DSE |
---|---|---|
Comments | Sensitivity: superiority test comparing CE-DSE and UE-DSE based on the difference | |
Type of Statistical Test | Superiority | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.0896 |
Comments | ||
Method | McNemar | |
Comments |
Statistical Analysis 2
Statistical Analysis Overview | Comparison Group Selection | CE-DSE - UE-DSE |
---|---|---|
Comments | Specificity: superiority test comparing CE-DSE and UE-DSE based on the difference | |
Type of Statistical Test | Superiority | |
Comments | ||
Statistical Test of Hypothesis | p-Value | <0.0001 |
Comments | ||
Method | McNemar | |
Comments |
Title | Reader-Specific Percentages of Participants Identified as Having a Critical Shift From Suboptimal to Optimal Echocardiographic Images |
---|---|
Description | The percentage of subjects with suboptimal images (defined as >= 2 adjacent segments with inadequate left ventricular endocardial border delineation (LV EBD) in any of the 3 apical views) at unenhanced stress echo converted to adequate (reduction of suboptimal segments in any of the 3 apical views) at contrast-enhanced stress echo |
Time Frame | Participants were followed until they had coronary angiography or up to 6 months post dose to collect clinical information on cardiac events if no coronary angiography was performed |
Outcome Measure Data
Analysis Population Description |
---|
The analysis population for EBD included all subjects who received Lumason and had EBD data available at peak stress for both UE-DSE and CE-DSE. |
Arm/Group Title | Reader 1 | Reader 2 | Reader 3 |
---|---|---|---|
Arm/Group Description | Reader 1 CE-DSE | Reader 2 CE-DSE | Reader 3 CE-DSE |
Measure Participants | 167 | 167 | 167 |
Number (95% Confidence Interval) [percentage of participants] |
84.4
48.8%
|
93.7
NaN
|
78.8
NaN
|
Title | Change in Total LV EBD |
---|---|
Description | Measured as the change in the total LV EBD score based on the 17 segments, from peak stress unenhanced vs. peak stress contrast-enhanced. Total LV EBD score ranges from 0 to 34 and higher score is better outcome. |
Time Frame | Participants were followed until they had coronary angiography or up to 6 months post dose to collect clinical information on cardiac events if no coronary angiography was performed |
Outcome Measure Data
Analysis Population Description |
---|
The analysis population for EBD included all subjects who received Lumason and had EBD data available at peak stress for both UE-DSE and CE-DSE. |
Arm/Group Title | UE-DSE | CE-DSE | Difference |
---|---|---|---|
Arm/Group Description | Unenhanced DSE | Contrast-enhanced DSE | (CE-DSE - UE-DSE) |
Measure Participants | 167 | 167 | 167 |
Reader 1 |
17.5
(10.83)
|
28.1
(8.32)
|
10.6
(11.98)
|
Reader 2 |
13.4
(8.57)
|
30.5
(4.81)
|
17.1
(7.87)
|
Reader 3 |
17.8
(7.04)
|
23.6
(7.47)
|
5.8
(9.17)
|
Title | Number of Participants With Adverse Events |
---|---|
Description | To obtain safety data in subjects administered Lumason during echocardiography |
Time Frame | up to 72 hours post dose |
Outcome Measure Data
Analysis Population Description |
---|
Safety analysis population includes all subjects who received Lumason |
Arm/Group Title | Lumason |
---|---|
Arm/Group Description | All patients were administered, Lumason (sulphur hexafluoride lipid-type A microspheres) an ultrasound contrast agent as a single 0.03 mL/kg bolus injection during echocardiography |
Measure Participants | 173 |
Number of subjects with adverse events (AE) |
21
12.1%
|
Number of subjects with AEs by intensity - Mild |
15
8.7%
|
Number of subjects with AEs by intensity -Moderate |
5
2.9%
|
Number of subjects with AEs by intensity - Severe |
1
0.6%
|
Number of subjects with serious AEs |
3
1.7%
|
Adverse Events
Time Frame | All adverse events (AE) that occurred from the time the subject signed the Informed Consent Form (ICF) until 72 hours after the last administration of Lumason or until the subject underwent cardiac intervention, whichever came first, were listed [recorded], [with predose AEs flagged in the subject data listings.] | |
---|---|---|
Adverse Event Reporting Description | ||
Arm/Group Title | Lumason | |
Arm/Group Description | Lumason (sulfur hexafluoride lipid-type A microspheres) 2 mL IV injection Lumason: Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography | |
All Cause Mortality |
||
Lumason | ||
Affected / at Risk (%) | # Events | |
Total | 0/173 (0%) | |
Serious Adverse Events |
||
Lumason | ||
Affected / at Risk (%) | # Events | |
Total | 3/173 (1.7%) | |
Cardiac disorders | ||
acute myocardial infarction | 1/173 (0.6%) | 1 |
Respiratory, thoracic and mediastinal disorders | ||
chronic obstructive pulmonary disease | 1/173 (0.6%) | 1 |
Vascular disorders | ||
phlebitis | 1/173 (0.6%) | 1 |
Other (Not Including Serious) Adverse Events |
||
Lumason | ||
Affected / at Risk (%) | # Events | |
Total | 21/173 (12.1%) | |
Cardiac disorders | ||
Bifascicular block | 1/173 (0.6%) | 1 |
Bradycardia | 1/173 (0.6%) | 1 |
Ventricular extrasystoles | 1/173 (0.6%) | 1 |
Ventricular tachycardia | 1/173 (0.6%) | 1 |
Gastrointestinal disorders | ||
Abdominal pain lower | 1/173 (0.6%) | 1 |
Mouth ulceration | 1/173 (0.6%) | 1 |
Nausea | 1/173 (0.6%) | 1 |
Vomiting | 1/173 (0.6%) | 1 |
General disorders | ||
Chest discomfort | 1/173 (0.6%) | 1 |
Chest pain | 1/173 (0.6%) | 1 |
Infections and infestations | ||
Bronchitis | 1/173 (0.6%) | 1 |
Gastrointestinal infection | 2/173 (1.2%) | 2 |
Nasopharyngitis | 2/173 (1.2%) | 2 |
Upper respiratory tract infection | 1/173 (0.6%) | 1 |
Investigations | ||
Blood glucose increased | 1/173 (0.6%) | 1 |
Electrocardiogram change | 1/173 (0.6%) | 1 |
Haematocrit increased | 1/173 (0.6%) | 1 |
Troponin increased | 1/173 (0.6%) | 1 |
Musculoskeletal and connective tissue disorders | ||
Pain in extremity | 1/173 (0.6%) | 1 |
Respiratory, thoracic and mediastinal disorders | ||
Oropharyngeal pain | 1/173 (0.6%) | 1 |
Vascular disorders | ||
Hypotension | 1/173 (0.6%) | 1 |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
Name/Title | Melda S. Dolan, MD, FACC, FASE, Head, Medical Affairs and Cardiac Ultrasound |
---|---|
Organization | Bracco Diagnostics Inc. |
Phone | 1-609-514-2506 |
Melda.Dolan@diag.bracco.com |
- BR1-141